Pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) are debilitating conditions characterized by elevated blood pressure in the pulmonary arteries, leading to progressive heart failure and reduced life expectancy. Current treatment options for these conditions are limited, often providing only symptomatic relief and failing to address the underlying pathophysiology. However, a recent publication in the Lancet Respiratory Medicine journal sheds light on a potential game-changer in the field of pulmonary hypertension treatment - seralutinib.
The TORREY Phase 2 study:Gossamer Bio, a leading clinical-stage biopharmaceutical company, has spearheaded the development of seralutinib as a potential therapeutic option for PAH and PH-ILD. The TORREY Phase 2 study manuscript
Comments